Bukwang Pharmaceutical Co., Ltd. (KRX:003000)

Market Cap	422.28B +28.5%
Revenue (ttm)	184.38B +32.7%
Net Income	9.74B
EPS	130.59
Shares Out	98.66M
PE Ratio	32.78
Forward PE	n/a
Dividend	50.00 (1.17%)
Ex-Dividend Date	Nov 4, 2025

Volume	623,134
Average Volume	849,839
Open	4,230.00
Previous Close	4,230.00
Day's Range	4,180.00 - 4,315.00
52-Week Range	3,200.00 - 5,160.00
Beta	0.64
RSI	63.25
Earnings Date	Feb 8, 2026

About Bukwang Pharmaceutical

Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, liver cirrhosis, and iron-deficiency anemia; over-the-counter drugs, such as fever and pain relief medication, gastrointestinal medication, cold medication...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1960
• Employees: 615
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 003000

Financial Performance

In 2024, Bukwang Pharmaceutical's revenue was 160.09 billion, an increase of 27.13% compared to the previous year's 125.93 billion. Losses were -2.64 billion, -91.57% less than in 2023.